Recombinant Antibodies in Cancer Therapy

descriptionPublicationkeyboard_double_arrow_right Article 01 Apr 2006 English Publisher:Bentham Science Publishers Ltd.Journal:Current Protein & Peptide Science, volume 7, pages 165-170 (issn: 1389-2037,

Copyright policy )

Authors: M S, Nayeem; Rizwan H, Khan;

doi: 10.2174/138920306776359768

pmid: 16611141

Recombinant Antibodies in Cancer Therapy

- Summary
- Subjects
- Metrics

Abstract

The application of recombinant immunotoxin and radioimmunoconjugate in Cancer therapy has revived the "magic bullet" concept predicted a century ago. Many of the recombinant antibodies have received FDA approval for various indication of cancer in recent years and numerous others are in clinical trials.

Related Organizations

Aligarh Muslim University
India

Keywords

Clinical Trials as Topic, Immunotoxins, Neoplasms, Antibodies, Monoclonal, Humans, Radioimmunotherapy, Recombinant Proteins

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	7
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%